Skip to main content
Clinical Trials/RBR-39ght5
RBR-39ght5
Active, not recruiting
未知

Efficacy and Durability of Botulinum Toxin in the Treatment of Bruxism - Double Randomized Blind Clinical Study

niversidade Ibirapuera0 sitesJanuary 21, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
patients wit bruxism
Sponsor
niversidade Ibirapuera
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 21, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Intervention

Investigators

Sponsor
niversidade Ibirapuera

Eligibility Criteria

Inclusion Criteria

  • Participants of both genders aged 18 to 70 years; participants complaining of clenching, compressing or grinding their teeth for at least 6 months; Masseter and temporal muscle hypertrophy; participants presenting: Headache / chronic orofacial pain, chewing pain, pain on palpation of the chewing and / or facial muscles (middle and lower third of the face).

Exclusion Criteria

  • Participants with BTX\-A or albumin allergy; participants have already had botulinum toxin treatment on these muscles for less than 12 months; pregnant or planning to become pregnant or lactating women; participants who are participating in other research involving other drugs; participants taking drugs that interfere with neuromuscular transmission (Aminoglycosides, Anticholinesterases, etc.) or who are taking antibiotics and corticosteroids; participants who are undergoing orthodontic treatment or using a bite plate.

Outcomes

Primary Outcomes

Not specified

Similar Trials